9.57
Precedente Chiudi:
$8.98
Aprire:
$9.28
Volume 24 ore:
2.32M
Relative Volume:
2.20
Capitalizzazione di mercato:
$737.75M
Reddito:
-
Utile/perdita netta:
$-209.96M
Rapporto P/E:
-3.0285
EPS:
-3.16
Flusso di cassa netto:
$-176.27M
1 W Prestazione:
+14.61%
1M Prestazione:
-4.40%
6M Prestazione:
-29.37%
1 anno Prestazione:
+81.59%
Replimune Group Inc Stock (REPL) Company Profile
Nome
Replimune Group Inc
Settore
Industria
Telefono
(781) 222-9600
Indirizzo
500 UNICORN PARK, WOBURN, MA
Confronta REPL con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
REPL
Replimune Group Inc
|
9.57 | 649.07M | 0 | -209.96M | -176.27M | -3.16 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-08-28 | Iniziato | ROTH MKM | Buy |
2023-04-17 | Ripresa | Piper Sandler | Overweight |
2021-11-19 | Iniziato | Piper Sandler | Overweight |
2021-10-15 | Ripresa | BTIG Research | Buy |
2020-11-17 | Iniziato | BTIG Research | Buy |
2020-11-02 | Iniziato | Jefferies | Buy |
2020-10-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2020-07-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
2020-05-05 | Iniziato | Barclays | Overweight |
2019-09-04 | Iniziato | ROTH Capital | Buy |
2019-07-23 | Iniziato | Chardan Capital Markets | Buy |
2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
2019-07-08 | Iniziato | H.C. Wainwright | Buy |
2019-04-25 | Iniziato | Wedbush | Outperform |
2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
2018-08-14 | Iniziato | JP Morgan | Overweight |
2018-08-14 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Replimune Group Inc Borsa (REPL) Ultime notizie
Replimune Group (NASDAQ:REPL) Price Target Raised to $22.00 at Piper Sandler - Defense World
Piper Sandler raises Replimune stock price target after updates - Investing.com Australia
Does Replimune Group Inc (NASDAQ: REPL) Still Need To Convince Analysts? - Stocksregister
Replimune Group (REPL) Price Target Raised by Piper Sandler Analyst | REPL Stock News - GuruFocus
Piper Sandler raises Replimune stock price target after updates By Investing.com - Investing.com India
Replimune (REPL) Price Target Raised by Piper Sandler Amid Positive Developments | REPL Stock News - GuruFocus
BNP Paribas Financial Markets Trims Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune (REPL) Highlights Promising RP1 Data at ASCO 2025 | REPL Stock News - GuruFocus
Replimune Presents New Analyses from the IGNYTE Study of RP1 plu - GuruFocus
Replimune Reports Promising Clinical Data for RP1 Plus Nivolumab at ASCO 2025, Highlighting Robust Responses and Safety Profile - Nasdaq
Replimune Presents New Analyses From The IGNYTE Study Of RP1 Plus Nivolumab In Anti-PD1 Failed Melanoma At The 2025 American Society Of Clinical Oncology (ASCO) Annual Meeting - marketscreener.com
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed ... - Enidnews.com
Replimune's RP1 Achieves 33% Response Rate in Anti-PD1 Failed Melanoma Trial | REPL Stock News - Stock Titan
ProShare Advisors LLC Grows Stock Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group (NASDAQ:REPL) Trading Down 5.9% – Time to Sell? - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of “Buy” from Analysts - Defense World
Replimune to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Nuveen Asset Management LLC - Defense World
Why Okta Stock Plunged on Wednesday - The Globe and Mail
HC Wainwright Estimates Replimune Group Q3 Earnings - Defense World
Leerink Partnrs Estimates Replimune Group Q1 Earnings - Defense World
Replimune’s SWOT analysis: biotech firm’s stock poised for growth amid FDA review - Investing.com India
Barclays Remains a Buy on Replimune Group (REPL) - The Globe and Mail
Replimune director sells $260,168 in common stock By Investing.com - Investing.com South Africa
Replimune Group, Inc. (NASDAQ:REPL) Q4 2025 Earnings Call Transcript - Insider Monkey
Replimune (REPL) Plans Major Stock Sale with 25.1M Shares Offeri - GuruFocus
Replimune Group Inc Files For Mixed Shelf Of Up To $250 MillionSEC Filing - marketscreener.com
Replimune (REPL) Announces $250 Million Securities Shelf Filing | REPL Stock News - GuruFocus
Replimune Group, Inc. (REPL) Stock Analysis: An Insight into a Biotech Gem with 141% Upside Potential - DirectorsTalk Interviews
Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance
Stock Traders Buy High Volume of Call Options on Replimune Group (NASDAQ:REPL) - Defense World
Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Replimune director sells $260,168 in common stock - Investing.com Australia
Replimune Group Advances Oncolytic Immunotherapy Pipeline - TipRanks
Replimune’s chief commercial officer sells $30,179 in stock By Investing.com - Investing.com South Africa
Replimune Group, Inc. SEC 10-K Report - TradingView
REPLIMUNE GROUP Earnings Results: $REPL Reports Quarterly Earnings - Nasdaq
Earnings call transcript: Replimune Q1 2025 sees stock drop post-earnings By Investing.com - Investing.com South Africa
Replimune (REPL) Prepares for Landmark Melanoma Treatment Launch - GuruFocus
Earnings call transcript: Replimune Q1 2025 sees stock drop post-earnings - Investing.com Australia
Replimune Group Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Transcript : Replimune Group, Inc., Q4 2025 Earnings Call, May 22, 2025 - marketscreener.com
Replimune Group, Inc. Reports Earnings Results for the Full Year Ended March 31, 2025 - marketscreener.com
Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides ... - Bluefield Daily Telegraph
Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update - TradingView
Northern Trust Corp Acquires 40,134 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group (NASDAQ:REPL) Stock Price Up 10.9% – What’s Next? - Defense World
Replimune Group: Analysts Are More Optimistic Than The Market (NASDAQ:REPL) - Seeking Alpha
Replimune Announces Dates for Fiscal Fourth Quarter and Year End - GuruFocus
Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day - The Manila Times
Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and - Bluefield Daily Telegraph
Replimune Group Inc Azioni (REPL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):